Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ola Landgren

Showing results (241-250 of 519) with videos related to

Pageof 52
Sort By:
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 22, 2010
Increased risk for lymphoid and myeloid neoplasms in elderly solid-organ transplant recipientsScott C Quinlan, Lindsay M Morton, Ruth M Pfeiffer, et al.
Haematologica|October 26, 2014
Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patientsCecilie Blimark, Erik Holmberg, Ulf-Henrik Mellqvist, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 26, 2019
Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL AmyloidosisHeather Landau, Oscar Lahoud, Sean Devlin, et al.
American Journal of Hematology|February 18, 2026
Excess Risk of Monoclonal Gammopathy in Patients With Gaucher DiseaseMajdolen Istaiti, Katie Thoren, Dickran Kazandjian, et al.
Clinical Pharmacology and Therapeutics|September 14, 2017
A Benefit-Risk Analysis Approach to Capture Regulatory Decision-Making: Multiple MyelomaG K Raju, Karthik Gurumurthi, Reuben Domike, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 30, 2019
Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysisHervé Avet-Loiseau, Heinz Ludwig, Ola Landgren, et al.
BMC Gastroenterology|November 5, 2016
Increased mortality among men aged 50 years old or above with elevated IgA anti-transglutaminase antibodies: NHANES IIIAlberto Rubio-Tapia, Jonas F Ludvigsson, Rok Seon Choung, et al.
Pathology|March 6, 2021
Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic useKylee H Maclachlan, Neil Came, Benjamin Diamond, et al.
Communications Biology|March 30, 2021
mmsig: a fitting approach to accurately identify somatic mutational signatures in hematological malignanciesEven H Rustad, Ferran Nadeu, Nicos Angelopoulos, et al.
International Journal of Cancer|December 13, 2007
Risks of cancer among a cohort of 23,935 men and women with osteoporosisKatherine A McGlynn, Gloria Gridley, Lene Mellemkjaer, et al.
Pageof 52

Showing results (241-250 of 519) with videos related to

Sort By:
Pageof 52
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 22, 2010
Increased risk for lymphoid and myeloid neoplasms in elderly solid-organ transplant recipientsScott C Quinlan, Lindsay M Morton, Ruth M Pfeiffer, et al.
Haematologica|October 26, 2014
Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patientsCecilie Blimark, Erik Holmberg, Ulf-Henrik Mellqvist, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 26, 2019
Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL AmyloidosisHeather Landau, Oscar Lahoud, Sean Devlin, et al.
American Journal of Hematology|February 18, 2026
Excess Risk of Monoclonal Gammopathy in Patients With Gaucher DiseaseMajdolen Istaiti, Katie Thoren, Dickran Kazandjian, et al.
Clinical Pharmacology and Therapeutics|September 14, 2017
A Benefit-Risk Analysis Approach to Capture Regulatory Decision-Making: Multiple MyelomaG K Raju, Karthik Gurumurthi, Reuben Domike, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 30, 2019
Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysisHervé Avet-Loiseau, Heinz Ludwig, Ola Landgren, et al.
BMC Gastroenterology|November 5, 2016
Increased mortality among men aged 50 years old or above with elevated IgA anti-transglutaminase antibodies: NHANES IIIAlberto Rubio-Tapia, Jonas F Ludvigsson, Rok Seon Choung, et al.
Pathology|March 6, 2021
Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic useKylee H Maclachlan, Neil Came, Benjamin Diamond, et al.
Communications Biology|March 30, 2021
mmsig: a fitting approach to accurately identify somatic mutational signatures in hematological malignanciesEven H Rustad, Ferran Nadeu, Nicos Angelopoulos, et al.
International Journal of Cancer|December 13, 2007
Risks of cancer among a cohort of 23,935 men and women with osteoporosisKatherine A McGlynn, Gloria Gridley, Lene Mellemkjaer, et al.
Pageof 52